Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Seerup Frandsen

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Lancet (London, England)|June 29, 2023
SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatideChristian Seerup Frandsen, Sten Madsbad
Maturitas|February 27, 2024
Perimenopausal abnormal uterine bleedingEva Dreisler, Christian Seerup Frandsen, Lian Ulrich
The Lancet. Diabetes & Endocrinology|March 13, 2016
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitusChristian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad
Expert Review of Clinical Pharmacology|March 29, 2017
Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetesLauge Østergaard, Christian Seerup Frandsen, Thomas Fremming Dejgaard, et al.
Expert Opinion on Pharmacotherapy|July 12, 2018
Non-insulin pharmacological therapies for treating type 1 diabetesChristian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad, et al.
Expert Opinion on Biological Therapy|March 2, 2016
Liraglutide for treating type 1 diabetesThomas Fremming Dejgaard, Christian Seerup Frandsen, Jens Juul Holst, et al.
BMJ Open|April 4, 2015
Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 studyThomas Fremming Dejgaard, Filip Krag Knop, Lise Tarnow, et al.
Frontiers in Endocrinology|April 30, 2019
Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 DiabetesChristian Stevns Hansen, Christian Seerup Frandsen, Jesper Fleischer, et al.
International Journal of Cardiology|October 7, 2018
Duration and complications of diabetes mellitus and the associated risk of infective endocarditisLauge Østergaard, Ulrik M Mogensen, Johan S Bundgaard, et al.
The Lancet. Diabetes & Endocrinology|December 15, 2015
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trialThomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Lancet (London, England)|June 29, 2023
SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatideChristian Seerup Frandsen, Sten Madsbad
Maturitas|February 27, 2024
Perimenopausal abnormal uterine bleedingEva Dreisler, Christian Seerup Frandsen, Lian Ulrich
The Lancet. Diabetes & Endocrinology|March 13, 2016
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitusChristian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad
Expert Review of Clinical Pharmacology|March 29, 2017
Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetesLauge Østergaard, Christian Seerup Frandsen, Thomas Fremming Dejgaard, et al.
Expert Opinion on Pharmacotherapy|July 12, 2018
Non-insulin pharmacological therapies for treating type 1 diabetesChristian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad, et al.
Expert Opinion on Biological Therapy|March 2, 2016
Liraglutide for treating type 1 diabetesThomas Fremming Dejgaard, Christian Seerup Frandsen, Jens Juul Holst, et al.
BMJ Open|April 4, 2015
Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 studyThomas Fremming Dejgaard, Filip Krag Knop, Lise Tarnow, et al.
Frontiers in Endocrinology|April 30, 2019
Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 DiabetesChristian Stevns Hansen, Christian Seerup Frandsen, Jesper Fleischer, et al.
International Journal of Cardiology|October 7, 2018
Duration and complications of diabetes mellitus and the associated risk of infective endocarditisLauge Østergaard, Ulrik M Mogensen, Johan S Bundgaard, et al.
The Lancet. Diabetes & Endocrinology|December 15, 2015
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trialThomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, et al.
Pageof 1